Research shows that GLP-1 agonists like semaglutide preserve muscle mass better than diet alone when combined with strength training, suggesting that tirzepatide's metabolic effects are neutral to positive for lean tissue when properly supported
The GLP-1 treatment area represents a long-term market opportunity, complementing the broader growth outlook for biosimilar and generic medicines
However, the evidence regarding its effects on specific outcomes, such as atrial fibrillation (AF), acute myocardial infarction, and chronic kidney disease, is still limited and inconsistent
Spacing doses at least two to three hours apart can reduce stomach irritation
The proposed mechanisms may involve the same binding proteins, with haptocorrin produced by some tumors and by the granulocytic response, raising the measured B12
A comprehensive approach addressing all contributing factors is typically necessary for optimal outcomes